GlassScriptPhysician profile
Kimberly Lemoine
NPI 1811941248
$29,992.77
in general payments reported to CMS, 2019-2025
30 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,289 · 2020: $11K · 2021: $4,414 · 2022: $2,841 · 2023: $3,582 · 2024: $1,101 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $1,249 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $1,249.02 |
| Education | $150.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26,859.60 | 2019-2024 | |
| Abbvie INC. | $687.12 | 2019-2023 | |
| Astellas Pharma US INC | $363.55 | 2019-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $244.22 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $221.66 | 2023-2025 | Myfembree |
| Merz North America, INC. | $202.04 | 2021-2022 | |
| Amgen INC. | $196.73 | 2020-2024 | Prolia, Evenity |
| Hologic Sales and Service, LLC | $124.57 | 2022-2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Novo Nordisk INC | $107.00 | 2023-2025 | Wegovy |
| Pfizer INC. | $100.23 | 2019-2023 | |
| Evofem Biosciences, INC. | $93.74 | 2021-2025 | Solosec, Phexx, Phexxi |
| Ethicon US, LLC | $74.19 | 2022 | |
| Myovant Sciences INC. | $70.12 | 2021-2022 | |
| Exeltis, USA INC. | $69.32 | 2019-2024 | Slynd |
| Avion Pharmaceuticals | $64.33 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $63.59 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $62.25 | 2022-2024 | |
| Lupin INC. | $57.66 | 2019-2021 | |
| Myriad Women'S Health, INC. | $51.63 | 2023 | Myrisk |
| Biohaven Pharmaceutical Holding Company LTD. | $51.29 | 2022 | |
| Meditrina | $39.19 | 2022 | |
| Radius Health, INC. | $38.53 | 2024-2025 | Tymlos |
| Medtronic, INC. | $34.04 | 2022-2023 | Truclear |
| Millicent US INC | $19.75 | 2025 | Femlyv |
| Biohaven Pharmaceuticals, INC. | $18.39 | 2021 | |
| Optumhealth Care Solutions, LLC | $18.03 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Virtus Pharmaceuticals LLC | $16.26 | 2021 | |
| Merck Sharp & Dohme LLC | $15.65 | 2019 | |
| Minerva Surgical, INC | $15.01 | 2025 | |
| Monaghan Medical Corporation | $13.08 | 2023 | Aeroeclipse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Lemoine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.